Dernières nouvelles pour Levi Strauss (NYSE:LEVI) Stock

LEVI STRAUSS & CO- CLASS A

Levi Strauss

Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.

Levi Strauss & Co

LEVIATHAN GOLD LTD by Leviathan Gold Ltd.

Leviathan Gold Ltd

Leviathan Gold Ltd Ordinary Shares

Levitee Labs Inc

High Roller Technologies ("High Roller" and the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROLR#NYSE">ROLR</a>), operator of award-winning premium online casino brands <a href="https://www.globenewswire.com/Tracker?data=8x8JWEQchVtbz2593OWl5lw-T0r-BbPkTWbhjsnuxDCln3v0CkMEx4cWkJtq2FSlHjr1JvC-jfYgGTiDvrlyUGuqCwHkddQpzHJ9gXLDyhI=">High Roller</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=lhbP1vbufkfCZkKUoAWlSj4VUP1BF5ZrOT8OF8Xh6Xdu-CUK1j46LZgzkvYNiTb524cZoS-t1gDShubCsBxUeA==">Fruta</a>, today announced a partnership with onboarding and identity solutions provider Checkin.com to leverage its ID verification products and services in Ontario.
High Roller has submitted its license application to enter Ontario's regulated online casino market, and subject to licensing and approval, the Company anticipates launching live operations in the market in H2 2025.

News

ROLR

High Roller Partners With Checkin.com To Leverage ID Verification Products And Services In Ontario

STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), the global leader in phakic IOLs with the EVO family of Implantable Collamer&#xAE; Lenses (EVO ICL&#x2122;) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020.
Separately, STAAR announced the formation of a new committee of its Board of Directors, the Capital Stewardship Committee, which will be chaired by Board member Lilian Y. Zhou. The Board determined to establish this new committee to help guide the Company's financial strategies, including the responsible allocation, management and oversight of capital. Ms. Zhou brings extensive experience in institutional investing and investment banking to chair this new committee. "Capital allocation is a key focus for STAAR given our growth prospects, strong cash flow generation, and opportunities to drive long-term value from our propriety Collamer&#xAE; material," said Ms. Zhou. "STAAR is dedicated to enhancing long-term shareholder returns, and I am excited to work with Steve and Deborah to drive STAAR's financial strategies and help build trust and credibility with investors."

Management

STAA

STAAR Surgical Appoints Deborah Andrews As CFO, Effective June 25, 2025

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCEHY

From NYSE To Hong Kong: Over 80 Chinese Firms Pull Plug On US Listings Amid Growing Tensions

<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights offering (the "Rights Offering") to all holders of record of the Company's ordinary shares as of 5:00 p.m. Eastern Time on July 9, 2025 (the "Record Date"). Under the Rights Offering, each holder of the Company's ordinary shares as of the Record Date will receive one right (the "Subscription Right") for each ordinary share held. Each Subscription Right will entitle the holder to subscribe for 0.1703 of a unit, each comprised of one ordinary share and a warrant to purchase one ordinary share at a subscription price of $1.00 per unit or, in lieu of such unit, one unit, each comprised of one pre-funded warrant to purchase one ordinary share and one warrant to purchase one ordinary share, at a subscription price of $0.9999 per unit. No fractional Subscription Rights are being distributed and no fractional units will be issued upon the exercise of any Subscription Rights in the Rights Offering. Shareholders must exercise Subscription Rights for at least one whole unit to participate in the Rights Offering. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on July 28, 2025, the expected expiration date of the Rights Offering. The Company may extend the period for exercising the Subscription Rights. Subscription Rights which are not exercised by the expiration date of the Rights Offering will expire and will have no value.
Assuming the Rights Offering is fully subscribed, the Company expects to receive aggregate gross proceeds of $10 million. Each holder of the Company's ordinary shares as of the Record Date may over-subscribe for additional units, which will be issued on a pro rata basis if the Rights Offering is not fully subscribed. Epoch Partner Investments Limited ("Epoch"), the Company's largest shareholder, has committed to participate in the Rights Offering and exercise its Subscription Right in full and any over-subscription privilege to purchase units not subscribed for by other shareholders with an aggregate subscription price of up to $5 million. Li Haixiang, the sole director of Epoch, is a member of the board of directors of the Company. As previously announced by the Company on May 21, 2025, Epoch granted IceCure a $2 million unsecured loan on May 17, 2025 bearing interest of 4.05% (the "Bridge Loan"). The Bridge Loan will be repaid after 12 months or upon the completion of the Rights Offering, whichever is earlier. The Company intends to use the proceeds of the Rights Offering, including proceeds directly raised from Epoch's participation in the Rights Offering, to repay the principal and any accrued interest from the Bridge Loan and for general corporate and working capital purposes.
The expected calendar for the rights offering is as follows:
<ul>
<li>July 8, 2025: Ownership Day – in order to be considered a shareholder of record on July 9, 2025, shares should be acquired by this date</li>
<li>July 9, 2025: Record Date (5:00 p.m. Eastern Time)</li>
<li>July 10, 2025: Distribution Date; Subscription Period Begins</li>
<li>July 28, 2025: Subscription Period Ends 5:00 p.m. Eastern Time</li>
</ul>

Offerings

ICCM

IceCure Medical Launches $10M Rights Offering At $1.00/Unit; Company's Largest Shareholder, Epoch Commits Up To $5M

<ul>
<li>TSLA</li>
<li>CRCL</li>
<li>BULL</li>
<li>AMD</li>
<li>NVDA</li>
<li>HOOD</li>
<li>ASTS</li>
<li>GOOGL</li>
<li>BBAI</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

ASTS

BBAI

BULL

CRCL

GOOGL

HOOD

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of June 25, 2025 (Via Swaggy Stocks)

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2), with broad <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">oncology treatment potential</a>.
CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
Kymera can receive up to $750 million in total payments, including up to $85 million in upfront and potential <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46091245/gilead-sciences-and-kymera-therapeutics-enter-into-exclusive-option-and-license-agreement-to-devel" rel="noreferrer noopener">option exercise payments</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
In addition, Kymera may receive tiered royalties ranging from the high single-digits to the mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program.
If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture, and commercialize all products resulting from the collaboration.
The transaction with Kymera is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2025 EPS by approximately $0.02-$0.03.
The core of this collaboration lies in the innovative approach of MGDs. Unlike traditional inhibitors that merely block the function of disease-driving proteins, MGDs work by selectively eliminating these proteins.
As Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences, stated, this mechanism &#8220;aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue.&#8221;
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics, highlighted that their &#8220;highly specific, orally active, CDK2 molecular glue degraders have demonstrated a compelling preclinical profile.&#8221;
Concurrently, Kymera Therapeutics announced an update on its IRAK4 partnership with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent, and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46091325/kymera-therapeutics-announces-sanofi-irak4-collaboration-update" rel="noreferrer noopener">into clinical studies</a>.
Following preclinical work supporting its development potential, KT-485 is being prioritized for development under the companies&#8217; existing IRAK4 collaboration and is expected to advance into Phase 1 testing next year.
Based on the planned development of KT-485, Sanofi <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30076238/kymera-therapeutics-stock-jumps-after-positive-data-from-atopic-dermatitis-trial" rel="noreferrer noopener">will not advance KT-474</a>.
Sanofi was conducting Phase 2 trials for hidradenitis suppurativa and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39675035/kymera-announces-expansion-of-kt-474-sar444656-hs-and-ad-phase-2-studies-following-interim-review-" rel="noreferrer noopener">atopic dermatitis indications</a>.
In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the companies&#8217; collaboration agreement terms.
Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485.
Kymera can receive up to $975 million of potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.
Price Action: SNY stock is down 0.76% at $48.05, KYMR stock is down 4.54% at $45, and GILD stock is down 0.28% at $106.90 during the premarket session at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46093513/sam-altman-crushes-openai-microsoft-feud-rumors-hails-really-wonderfully-good-bond-with-satya-nadella" target="_blank" rel="noreferrer noopener">Sam Altman Crushes OpenAI-Microsoft Feud Rumors, Hails &#8216;Really Wonderfully Good&#8217; Bond With Satya Nadella</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

Health Care

Movers

General

GILD

KYMR

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Bowman Consulting Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>), a national engineering services and program management firm, was awarded a continuation contract to provide aerial acquisition and orthoimagery services under a new Phase II contract for the National Resource Inventory (NRI) program. The work is to be performed under contract with the Farm Production and Conservation of the United States Department of Agriculture (USDA-FPAC). Building on the completion of the initial task order in 2024, Bowman is supporting most of the program's data collection efforts covering roughly 11.2 million acres across the United States.
The USDA's NRI program assesses the status, condition and trends of land, soil, water and related natural resources nationwide. This year, the program will survey approximately 70,000 sites averaging 160 acres per site. This win builds on Bowman's decades long history of supporting the USDA, the NRI and other related initiatives.

BWMN

Bowman Consulting Group Awarded Continuation Contract To Provide Aerial Acquisition And Orthoimagery Services Under New Phase II Contract For NRI Program

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is actively trading around our key pivot at 607.55. Bulls should look for initial momentum above 608.35. Sustained strength beyond this zone would target a move towards 609.33, and if this level solidifies during the session, a further push upwards to 610.63 becomes likely. Our optimistic bull scenario has SPY reaching as high as 611.39.&nbsp;
If 607.55 falters and selling pressure emerges, bears will aim first at the critical test at 606.34. Failure to hold here would encourage further downside exploration towards 605.41. Intensified bearish momentum might press prices lower to significant support at 604.45, and under severe selling conditions, SPY could target the lower boundary at 603.38.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is hovering near our important pivot at 540.60. Bulls aim for a decisive push above 542.31, reinforcing it as a stable floor. Holding firmly here would encourage further bullish activity targeting 543.58. Continued upward momentum could propel price action to 545.14, and strong auction conditions might enable a reach towards our bullish peak target of 550.60.&nbsp;
Conversely, if QQQ struggles below the pivotal 540.60, bears will swiftly move to test downside strength at 539.02. Persistent selling here would lead bears to target the next key support at 538.06. A breach here invites deeper downside risk, bringing 536.95 into focus, and sustained weakness could push towards the daily bear target of 535.30.
Apple Inc. (AAPL)
Apple is presently negotiating our significant level at 200.53. Bullish sentiment would benefit from buyers establishing clear support here, opening a path upwards to 202.29. Continued buying pressure could lift prices towards 203.48, and sustained bullish dominance throughout today&#8217;s session sets a high target of 204.33.&nbsp;
However, if Apple loses grip on 200.53, sellers will challenge lower supports starting at 199.51. Continued bearish activity would aim for further downside at 198.79, with persistent selling potentially testing deeper support at 198.22. An aggressive bearish session could drive Apple towards our downside target of 197.69.
Microsoft Corp. (MSFT)
Microsoft is currently trading near our pivotal zone at 491.33. Bulls seek firm control above this price, enabling an advance towards 493.62 and solidifying it as intraday support. Sustained bullish pressure could propel the market towards 495.11, and continuous upside momentum would target today&#8217;s optimistic bullish mark at 496.90.&nbsp;
Conversely, if Microsoft fails to stabilize above 491.33, bears will promptly target downside support at 489.88. A breakdown here would open further bearish opportunities toward 488.74. Continuous selling could see prices pressured lower towards 487.59, with heightened bearish activity potentially reaching today&#8217;s bearish boundary at 486.72.
NVIDIA Corporation (NVDA)
NVIDIA currently trades near the critical area of 148.52. Bullish conviction aims to push price above 150.32, establishing firm support there. Continued buying could propel the auction upward towards 151.99, with ongoing positive momentum potentially driving NVIDIA higher to 153.23. Our optimistic bullish projection sets a peak target at 154.64.&nbsp;
If NVIDIA fails to maintain stability above 148.52, bears will promptly test downward strength at 147.06. A breach here could lead to additional weakness down to 145.61, with intensified selling pressure challenging support around 144.21. A severe bearish environment today might push prices to our lower bear target at 143.41.
Alphabet Inc Class A (GOOGL)
Alphabet is actively trading around the crucial pivot of 167.04. For the bullish outlook, buyers must strongly defend this level and initiate a rise toward 169.34. Continuous bullish action could see prices ascend further, potentially reaching our optimistic bullish scenario target at 171.14.&nbsp;
Conversely, failure to hold 167.04 would see bears aiming at the immediate downside support of 165.41. Should sellers dominate further, the market could push lower towards 163.79. A heavily bearish environment might drag Alphabet down to the day&#8217;s lowest target at 161.79.
Meta Platforms Inc (META)
Meta currently negotiates around our significant pivot at 714.27. Bulls will seek robust trading above 716.39, turning it into solid support and enabling a push towards 717.87. Sustained buying enthusiasm would then target a higher level at 720.11, with strong bullish sentiment potentially carrying Meta to today&#8217;s optimistic upside target of 721.50.&nbsp;
Should Meta falter at holding 714.27, bears will swiftly capitalize, driving price downward to 712.14 initially. Continued selling momentum would aim to test lower at 708.06. If bears maintain control aggressively, the price could test our daily bearish target of 704.07.
Tesla Inc. (TSLA)
Tesla is currently oscillating near our pivotal price of 340.97. For a bullish progression, traders aim to firmly push above 346.64. Sustained positive momentum could elevate Tesla towards 350.87. If broader market conditions are favorable, higher trading levels at 356.80 become feasible, with our ambitious bullish target positioned at 363.84.&nbsp;
However, if Tesla loses ground below 340.97, bears will likely drive prices swiftly downward toward 333.93. Continued bearish activity could push the auction lower to 327.59, and persistent selling momentum might expose deeper downside potential, targeting today&#8217;s bearish floor at 322.52.
Final Word: Today brings crucial economic data starting with May&#8217;s New Home Sales at 10 AM ET, followed by the Treasury&#8217;s 2-Year Floating Rate Note auction at 11:30 AM ET and the 5-Year Note auction at 1 PM ET. Jerome Powell returns to Capitol Hill at 10 AM ET, testifying before the Senate Banking Committee. While his initial remarks are unchanged from yesterday, market sensitivity will heighten during the interactive Q&amp;A session. Expect volatility, especially around Powell's commentary, as traders interpret his responses for monetary policy clues. Keep risk management strict and trade with clarity today.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

How To Trade SPY, Top Tech Stocks As Focus Turns To May New Home Sales

WIIM

MULN

Mullen Automotive shares are trading higher after the company announced it is now accepting Bitcoin and TRUMP Coin for EV purchases.

Baird analyst Luke Junk maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Neutral and raises the price target from $4 to $5.

Price Target

Analyst Ratings

Baird Maintains Neutral on BlackBerry, Raises Price Target to $5

<a href="https://www.globenewswire.com/Tracker?data=Xh3dnx7bd9ZsfQVfM-pJGVrq5AFikCMwonz-rxJuGZM7iIAshhT3szNwdNmLV8wH1Mva7G52IZeQmBnXmgnTflhvqHVULt4s7bTo0ZOx3Gw=">Mullen Automotive, Inc.</a> (NASDAQ:<a href="https://www.globenewswire.com/Tracker?data=EfgpfV9WrmnsUtly_LfIvEM-3lCJKaQ9foV0byhXKXdwio9oe8M3vTFSG5pZt9Y8AcBwV6fQPVX3NjLqExLdRtqqQ3OYYiiJUIjI5QyCSZ6fI--EPQ-6CDHzQBom9zgY"> MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that the Company is accepting cryptocurrency ("crypto"), including Bitcoin and the $TRUMP meme coin, for the purchase of both Mullen and Bollinger commercial electric vehicles.
The Company is currently one of the only vehicle manufacturers to accept cryptocurrency as payment form on vehicle purchases. The Company is also investigating acceptance of additional types of crypto, including other popular meme and stable coins.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Mullen Automotive Now Accepting Bitcoin And $TRUMP Meme Coin For EV Purchases; Explores More Crypto Options

ZYXI

Zynex Secures UK Patent For Multiparameter, Noninvasive Sepsis Monitor

LFWD

Lifeward shares are trading lower after the company announced the pricing of a $2.6 million public offering of 4 million shares and warrants at a combined price of $0.65 per share and associated ordinary warrant.

Baird analyst Colleen Kusy maintains Nuvalent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) with a Outperform and raises the price target from $105 to $112.

NUVL

Baird Maintains Outperform on Nuvalent, Raises Price Target to $112

BLNE

Beeline Holdings shares are trading higher after the company announced its subsidiary, Beeline Title holdings, closed its first crypto real estate transactions.

BMBL

BMBL stock has given up its prior loss. Bumble share were trading lower after the company announced it is reducing the size of its team.

Shares of KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) traded higher on Tuesday after the company reported <a href="https://www.benzinga.com/markets/earnings/25/06/46063325/kb-home-q2-earnings-revenue-eps-beat-estimates-homebuilder-lowers-2025-housing-revenue-outlook-as-market-conditions-soften">upbeat fiscal second-quarter revenues a day earlier.</a>
The announcement came amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
BofA Securities On KB Home
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/596530e4988ca80001209fc0/rafe-jadrosich">Analyst Rafe Jadrosich</a> maintained a Buy rating, while cutting the price target from $58 to $54.
Although KB Home reported in-line earnings for its fiscal second quarter, it lowered its full-year revenue and margin guidance, Jadrosich said in a note. The company had net orders of 3,500, missing expectations and representing a 13% year-on-year decline, he added.
"KBH continued to lower base home prices in underperforming communities," the analyst wrote. Management reduced their revenue guidance from $6.6 billion-$7 billion to $6.3 billion-$6.5 billion and their margin guidance from 19.2%-20% to 19%-19.4% "due to lower deliveries and regional mix," he further stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
JPMorgan On KB Home
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f9fdc60bd991000159a4c3/michael-rehaut">Analyst Michael Rehaut</a> reiterated a Neutral rating on the stock.
Although KB Home reported in-line earnings, its gross margin contracted by 60 basis points (bps) sequentially and by 150 bps year-on-year to 19.7%, Rehaut said. The company's absorption rate, which indicates the pace of sales, declined to 17%, worse than expectations of a decline of 14%.
Management lowered their full-year guidance "across most metrics," the analyst wrote. The company's lowered gross margin outlook reflects a year-on-year contraction between 170 and 210 bps, he further stated.
KBH Price Action: Shares of KB Home were up 4.74% to $82.44 on Tuesday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46078855/kb-home-analysts-slash-their-forecasts-after-q2-earnings">KB Home Analysts Slash Their Forecasts After Q2 Earnings</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Earnings

Reiteration

KB Home Stock Jumps After Q2 Report, But Forecasts Leave Analysts Divided

<a href="https://www.wolfpackresearch.com/items/cto%3A-the-b.-riley-of-reits" title="https://www.wolfpackresearch.com/items/cto%3A-the-b.-riley-of-reits">https://www.wolfpackresearch.com/items/cto%3A-the-b.-riley-of-reits</a>

Short Sellers

Watching CTO Realty Growth; Wolfpack Research Issues Report On The Co Stating They Are Short

RSLS

ReShape Lifesciences shares are trading higher after the company announced it was granted an institutional patent from the Australian Patent Office for its Diabetes Neuromodulation technology.

Lifeward Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company's ordinary shares, at a combined public offering price of $0.65 per ordinary share and associated ordinary warrant. The ordinary warrants will have an exercise price of $0.65 per ordinary share, will be exercisable immediately upon issuance and will expire on the five-year anniversary of the issuance date. The closing of the offering is expected to occur on or about June 26, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately $2.6 million before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the ordinary warrants, if fully exercised on a cash basis, will be approximately $2.6 million. No assurance can be given that any of the ordinary warrants will be exercised. The Company intends to use the net proceeds from this offering for its continuing commercial efforts, working capital and general corporate purposes.

Lifeward Prices $2.6M Public Offering Of 4M Shares And Warrants At A Combined Price Of $0.65

Press Releases

Levi Strauss & Co. Receives Ratings Upgrade from Fitch Ratings

Beyoncé and Levi's® Launch Chapter 2 with REIIMAGINE: Pool Hall

Levi Strauss & Co. Announces Participation in Upcoming Investor Conferences

Levi Strauss & Co. to Webcast First Quarter 2025 Earnings Conference Call

Levi Strauss & Co. Reports Better Than Expected First-Quarter 2025 Financial Results

Beyoncé and Levi's® Launch Chapter 3 with REIIMAGINE: Refrigerator

Levi Strauss & Co. Unveils Plans for 25 New Murals Across San Francisco

Levi Strauss & Co. Enters into Definitive Agreement to Sell Dockers® to Authentic Brands Group

Levi Strauss & Co. Announces Participation at the Deutsche Bank Global Consumer Conference

Comments

Levi Strauss

Actualités

Dernières nouvelles pour Levi Strauss (NYSE:LEVI) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL